medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2013, Número 03-04

<< Anterior Siguiente >>

Medicina & Laboratorio 2013; 19 (03-04)


Carcinoma in situ de la mama: actualización

Gallego NGA, Velázquez VJ

Idioma: Español
Referencias bibliográficas: 121
Paginas: 127-160
Archivo PDF: 1275.31 Kb.


RESUMEN

Los carcinomas in situ de la mama son el primer estado de cáncer de mama morfológicamente reconocible y pueden evolucionar a un carcinoma de mama invasivo, aunque se desconoce la tasa precisa de progresión. Debido a que el carcinoma ductal in situ es un predictor de carcinoma ductal invasivo en el futuro, es importante la participación de la paciente en la toma de decisiones sobre el tratamiento; actualmente, existen indicaciones precisas para realizar tratamiento conservador o radical, pero cada caso se debe analizar en forma independiente. Por su parte, el carcinoma lobulillar in situ es solo un marcador de riesgo de carcinoma invasivo, muchas de las pacientes no requieren tratamiento y se pueden dejar bajo observación. En este módulo se presentan los avances sobre el carcinoma in situ de mama en sus dos variedades, ductal y lobulillar, en lo relacionado con las manifestaciones clínicas, las alteraciones genéticas, el diagnóstico, el pronóstico, el tratamiento y el seguimiento. De igual forma, se hará una actualización de la enfermedad de Paget.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Koss LG, Melamed MR, editors. Koss’ diagnostic cytology and Its histopathologic bases (ed 5). United States: Lippincott Williams & Wilkins; 2006.

  2. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011; 223: 307- 317.

  3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.

  4. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, et al. Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 2007; 177: 87-101.

  5. Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 2002; 16: 693-706.

  6. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36 Suppl 1: 59-72.

  7. Brown JP, Pinder SE. Ductal carcinoma in situ: current morphological and molecular subtypes. Diagnostic Histopathology 2012; 18: 112-118.

  8. Glover JA, Bannon FJ, Hughes CM, Cantwell MM, Comber H, Gavin A, et al. Increased diagnosis and detection rates of carcinoma in situ of the breast. Breast Cancer Res Treat 2012; 133: 779-784.

  9. Barnes NL, Ooi JL, Yarnold JR, Bundred NJ. Ductal carcinoma in situ of the breast. BMJ 2012; 344: e797.

  10. Skinner KA, Silverstein MJ. The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer 2001; 8: 33-45.

  11. Silverstein MJ, Woo C. Carcinoma ductal in situ: controversias diagnósticas y terapéuticas. In: Bland KI, Copeland III E, eds. La mama Manejo multidisciplinario de las enfermedades benignas y malignas (ed 3). Buenos Aires: Editorial Médica Panamericana; 2007: 1029-1062.

  12. Aguilar-Bernier M, de Troya-Martín M, Blázquez- Sánchez N, García-Rodrigo I, Maañón C, Blanco- Eguren G. Enfermedad de Paget de la mama: análisis descriptivo de cinco pacientes. Piel 2008; 23: 400- 404.

  13. Haagensen CD. Enfermedades de la mama. Buenos Aires: Editorial Médica Panamericana; 1987.

  14. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441.

  15. Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 2008; 112: 2130-2142.

  16. Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 8244-8252.

  17. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204.

  18. Hwang ES, DeVries S, Chew KL, Moore DH, 2nd, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004; 10: 5160-5167.

  19. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999; 187: 396- 402.

  20. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001; 93: 1811-1817.

  21. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997; 89: 76-82.

  22. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 2003; 78: 7-15.

  23. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.

  24. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253.

  25. Menes TS, Kerlikowske K, Jaffer S, Seger D, Miglioretti DL. Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18: 2822-2828.

  26. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102: 170-178.

  27. Hindle WH. In situ breast carcinoma: diagnosis and treatment. Clin Obstet Gynecol 2002; 45: 774-777.

  28. Goto M, Yuen S, Akazawa K, Nishida K, Konishi E, Kajihara M, et al. The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy. Eur Radiol 2012; 22: 1255-1264.

  29. Kneeshaw PJ, Lowry M, Manton D, Hubbard A, Drew PJ, Turnbull LW. Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging. Breast 2006; 15: 29-38.

  30. Kropcho LC, Steen ST, Chung AP, Sim MS, Kirsch DL, Giuliano AE. Preoperative breast MRI in the surgical treatment of ductal carcinoma in situ. Breast J 2012; 18: 151-156.

  31. Vanderwalde LH, Dang CM, Bresee C, Phillips EH. Discordance between pathologic and radiologic tumor size on breast MRI may contribute to increased re-excision rates. Am Surg 2011; 77: 1361-1363.

  32. Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ. Diagnosis and management of ductal carcinoma in situ (DCIS). Evid Rep Technol Assess (Full Rep) 2009: 1-549.

  33. Olarte G. Guías de manejo de tumores mamarios. Revista Colombiana de Obstetricia y Ginecología 1999; 48: 3-40.

  34. McNelis J, Wise L. Carcinoma in situ. Clin Obstet Gynecol 1994; 37: 988-992.

  35. Lourenco AP, Mainiero MB, Lazarus E, Giri D, Schepps B. Stereotactic breast biopsy: comparison of histologic underestimation rates with 11- and 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol 2007; 189: W275-279.

  36. Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011; 260: 119-128.

  37. Marchant DJ. Breast Disease. Philadelphia: Saunders Company; 1997.

  38. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 2009; 133: 15-25.

  39. Jaffer S, Bleiweiss IJ. Histologic classification of ductal carcinoma in situ. Microsc Res Tech 2002; 59: 92- 101.

  40. Badruddoja M. Ductal carcinoma in situ of the breast: a surgical perspective. Int J Surg Oncol 2012; 2012: 761364.

  41. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol 1991; 47: 139-147.

  42. Sakorafas GH, Farley DR, Peros G. Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 2008; 34: 483- 497.

  43. Silverstein MJ, Barth A, Waisman JR, Colburn WJ, Gierson ED, Gamagami P. Predicting local recurrence in patients with intraductal breast carcinoma (DCIS). Proc Am Soc Clin Oncol 1995; 14: 117.

  44. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 340: 1455-1461.

  45. de Deus Moura R, Wludarski SC, Carvalho FM, Bacchi CE. Immunohistochemistry applied to the differential diagnosis between ductal and lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol 2012.

  46. Gupta S, Deka L, Gupta R, Pant L, Singh S. Molecular phenotypes of ductal carcinoma-in-situ and invasive ductal carcinoma: a comparative study. Indian J Pathol Microbiol 2012; 55: 43-46.

  47. Arrechea-Irigoyen MA, Vicente-García F, Córdoba- Iturriagagoitia A, Ibáñez-Beroiz B, Santamaría-Martínez M, Guillén-Grima F. Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas. . Anales Sis San Navarra 2011; 34: 219-233.

  48. Steinman S, Wang J, Bourne P, Yang Q, Tang P. Expression of cytokeratin markers, ER-alpha, PR, HER- 2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 2007; 37: 127-134.

  49. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.

  50. Yu J, Monaco SE, Onisko A, Bhargava R, Dabbs DJ, Cieply KM, et al. A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast. Hum Pathol 2012.

  51. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 21 Suppl 2: S8-S15.

  52. Fisher ER. Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast. CA Cancer J Clin 1997; 47: 52-64.

  53. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med 1997; 127: 1013-1022.

  54. van de Vijver MJ. Biological variables and prognosis of DCIS. Breast 2005; 14: 509-519.

  55. Quinn CM, Ostrowski JL. Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast. J Clin Pathol 1997; 50: 596-599.

  56. Hetelekidis S, Schnitt SJ, Morrow M, Harris JR. Management of ductal carcinoma in situ. CA Cancer J Clin 1995; 45: 244-253.

  57. Hughes KS, Lee AK, Rolfs A. Controversies in the treatment of ductal carcinoma in situ. Surg Clin North Am 1996; 76: 243-265.

  58. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14: 370-378.

  59. Silverstein MJ. Ductal carcinoma in situ of the breast: controversial issues. Oncologist 1998; 3: 94-103.

  60. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.

  61. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77: 2267-2274.

  62. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995; 31A: 1425-1427.

  63. Silverstein MJ. The University of Southern California/ Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186: 337-343.

  64. Goldstein NS, Vicini FA, Kestin LL, Thomas M. Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. Cancer 2000; 88: 2553-2560.

  65. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999; 86: 429-438.

  66. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995; 45: 199-226.

  67. Sigal-Zafrani B, Lewis JS, Clough KB, Vincent-Salomon A, Fourquet A, Meunier M, et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol 2004; 17: 81-88.

  68. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362: 95-102.

  69. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355: 528- 533.

  70. Bass SS, Dauway E, Mahatme A, Ku NN, Berman C, Reintgen D, et al. Lymphatic mapping with sentinel lymph node biopsy in patients with breast cancers <1 centimeter (T1A-T1B). Am Surg 1999; 65: 857-861; discussion 861-852.

  71. Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138: 309-313.

  72. Perry F, Figueredo C, Ossa C, Guzmán L, Castillo J, Ángel J, et al. Ganglio centinela en cáncer de mama: experiencia 2000-2010 en el Instituto Nacional de Cancerología de Colombia. Rev Col Cancerología 2012; 16: 234-239.

  73. van Deurzen CH, Hobbelink MG, van Hillegersberg R, van Diest PJ. Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. Eur J Cancer 2007; 43: 993- 1001.

  74. Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg 2008; 247: 315-319.

  75. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.

  76. Kerin MJ, McAnena OJ, O’Malley VP, Grimes H, Given HF. CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76: 838-839.

  77. O’Hanlon DM, Kerin MJ, Kent PJ, Skehill R, Maher D, Grimes H, et al. A prospective evaluation of CA15- 3 in stage I carcinoma of the breast. J Am Coll Surg 1995; 180: 210-212.

  78. Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991; 7: 162-166.

  79. Hayes DF, Zurawski VR, Jr., Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542-1550.

  80. Barak V, Carlin D, Sulkes A, Treves A, Biran S. CA15- 3 serum levels in breast cancer and other malignancies-- correlation with clinical course. Isr J Med Sci 1988; 24: 623-627.

  81. Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2012.

  82. Ichihara S, Aoyama H. Intraductal carcinoma of the breast associated with high levels of circulating tumor- associated antigens (CA 15-3 and NCC-ST-439). Cancer 1994; 73: 2181-2185.

  83. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737-769.

  84. Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer 2006; 42: 2205-2211.

  85. Page DL, Kidd TE, Jr., Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991; 22: 1232-1239.

  86. Schwartz GF. Biología y conducta terapéutica del carcinoma lobulillar in situ de la mama. In: Bland KI, Copeland III E, eds. La mama Manejo multidisciplinario de las enfermedades benignas y malignas (ed 3). Buenos Aires: Editorial Médica Panamericana; 2007: 1029-1062.

  87. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW, Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978; 2: 225-251.

  88. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 1979; 189: 377-382.

  89. Sapino A, Frigerio A, Peterse JL, Arisio R, Coluccia C, Bussolati G. Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch 2000; 436: 421-430.

  90. Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol 2008; 98: 314-317.

  91. Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998; 58: 4721-4727.

  92. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 2003; 5: 313-319.

  93. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006; 4: 511-522.

  94. Sung JS, Malak SF, Bajaj P, Alis R, Dershaw DD, Morris EA. Screening breast MR imaging in women with a history of lobular carcinoma in situ. Radiology 2011; 261: 414-420.

  95. Hanby AM, Hughes TA. In situ and invasive lobular neoplasia of the breast. Histopathology 2008; 52: 58- 66.

  96. Jacobs TW, Pliss N, Kouria G, Schnitt SJ. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001; 25: 229-236.

  97. Gao F, Carter G, Tseng G, Chivukula M. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies. Am J Clin Pathol 2010; 133: 767-771.

  98. Newman W. Lobular carcinoma of the female breast. Report of 73 cases. Ann Surg 1966; 164: 305-314.

  99. DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M. Prognosis in infiltrating lobular carcinoma. An analysis of “classical” and variant tumors. Am J Surg Pathol 1990; 14: 12-23.

  100. Mohsin SK, O’Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 2005; 90: 249-256.

  101. Tavassolli FA, Devilee P, editors. 43 World health organization. Clasification of tumors. Pathology and genetics of tumors of the breast and female genital organs .Tumors of the breast Lyon: IARC; 2003.

  102. Simpson PT, Gale T, Fulford LG, Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003; 5: 258-262.

  103. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000; 24: 1650-1656.

  104. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002; 15: 1044-1050.

  105. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol 2008; 32: 1721- 1726.

  106. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) guidelines. 2012. www.nccn.org Consultado el 15 de mayo de 2012.

  107. Levi F, Randimbison L, Te VC, La Vecchia C. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer 2005; 116: 820-823.

  108. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005; 23: 5534-5541.

  109. Cangiarella J, Guth A, Axelrod D, Darvishian F, Singh B, Simsir A, et al. Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy?: a report of 38 cases and review of the literature. Arch Pathol Lab Med 2008; 132: 979-983.

  110. Ghofrani M, Tapia B, Tavassoli FA. Discrepancies in the diagnosis of intraductal proliferative lesions of the breast and its management implications: results of a multinational survey. Virchows Arch 2006; 449: 609-616.

  111. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.

  112. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.

  113. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89.

  114. Zheng S, Song QK, Zhao L, Huang R, Sun L, Li J, et al. Characteristics of mammary Paget’s disease in China: a national-wide multicenter retrospective study during 1999-2008. Asian Pac J Cancer Prev 2012; 13: 1887-1893.

  115. Sakorafas GH, Blanchard DK, Sarr MG, Farley DR. Paget’s disease of the breast: a clinical perspective. Langenbecks Arch Surg 2001; 386: 444-450.

  116. Nance FC, DeLoach DH, Welsh RA, Becker WF. Paget’s disease of the breast. Ann Surg 1970; 171: 864- 874.

  117. Polanco D, Manzanedo I, Bouayadi L, Núñez G, Tartas A. Enfermedad de Paget perianal. Rev Chilena de Cirugía 2010; 62: 623-626.

  118. Ikeda DM, Helvie MA, Frank TS, Chapel KL, Andersson IT. Paget disease of the nipple: radiologic-pathologic correlation. Radiology 1993; 189: 89-94.

  119. Sawyer RH, Asbury DL. Mammographic appearances in Paget’s disease of the breast. Clin Radiol 1994; 49: 185-188.

  120. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, et al. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 2012; 36: 1353-1358.

  121. Fourquet A, Campana F, Vielh P, Schlienger P, Jullien D, Vilcoq JR. Paget’s disease of the nipple without detectable breast tumor: conservative management with radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13: 1463-1465.




2020     |     www.medigraphic.com